NO SIGNIFICANT RESPONSE OF SERUM TNF-Α TO SINGLE BOUT EXERCISE IN ADULT OBESE INDIVIDUALS

ABSTRACT Accumulating evidence suggest that obesity is associated with low grade inflammation. TNF-α is an inflammatory cytokine and related with insulin resistance and chronic metabolic diseases. In present study, we aimed to determine acute and recovery response of serum TNF-α to one bout exercise in nontrained adult obese men aged 39.2 (1.60) years and 93 (7.5) kg of body weight. Blood samples were obtained pre and immediately and 60 min and 24 hour after exercise test in fourteen non-trained obese men. Significant difference in serum TNF-α between pre-test and acute or recovery response to exercise test was determined by repeated-measures ANOVA. Data by statistical analysis showed no significant differences in serum TNF-α between pre-test and acute or recovery response to exercise. Based on these data, it is concluded that acute moderate exercise can not affect acute or recovery of serum TNF-α in obese subjects

Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial

Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial in MS clinic in a university hospital in Isfahan from 2014 to 2016. They were randomly assigned to two groups receiving high dose interferon beta-1a (Recigen) or Fingolimod. The number of relapses, EDSS, and Magnetic Resonance Imaging (MRI) findings were evaluated at the beginning, 3, 9, 12, and 18 months after intervention. The t-test and Mann Whitney U test and ANCOVA in SPSS version 20 were used. Results: A total of 120 MS patients with the mean age of 38.07±9.0 years included in this study and 35.8% of whom were males. The mean EDSS was lower in Fingolimod group from the 9th month to the end of intervention (1.80±1.05 vs. 2.17±0.95 in the 9th month and 1.95±0.92 vs. 2.30±0.96 in 18th month). The mean number of relapses was lower in Finglimod group significantly in the 12th and 18th months (0.91±0.76 vs. 1.27±0.77 in the 12th and 0.6±0.55 vs 1.0±0.71 in the 18th month). The mean values of new T2 lesions (1.00 vs. 1.47) and gadolinium enhancing lesions (0.467 vs. 0.817) were lower in Fingolimod group at the end of the study. Conclusion: Both treatments were beneficial with a significant superiority of Fingolimod

Effects of six weeks of aerobic training on the protein levels of Aβ-40 and IGF-1 in the hippocampus of diabetic rats

Background: Functional disorder of the nervous system is one of the consequences of type 2 diabetes. Aβ-40 and IGF-1 are probably involved in this mechanism. Therefore, the present study aimed to investigate the effect of aerobic training on Aβ-40 and IGF-1 proteins in the hippocampus of rats with type 2 diabetes. Materials and Methods: A total of 32 8-week-old male Wistar rats were placed in 4 groups: control (C), diabetes (D), diabetes training (DT), and training (T). Diabetes was induced by streptozotocin injection. The training was performed for six weeks. To measure proteins, the ELISA method was used, and a one-way ANOVA test was used for data analysis. Results: The amount of Aβ-40 in group D was different from that of DT, T, and C groups (P.05). The amount of IGF-1 in the T group was different only from the D group (P=0.001). The positive (Aβ-40) and negative (IGF-1) correlations were observed with blood glucose (P=0.001, r=0.850 and P=0.001, r=-0.814). Conclusion: Diabetes increases Aβ-40 and decreases IGF-1. Nevertheless, exercise moderates the effect of diabetes on them. Considering the appropriate duration of exercise and the correlation of these proteins with blood glucose, an increase in the intensity of aerobic training may further regulate the negative effect of diabetes on these two proteins

123VCF: an intuitive and efficient tool for filtering VCF files

Abstract Background The advent of Next-Generation Sequencing (NGS) has catalyzed a paradigm shift in medical genetics, enabling the identification of disease-associated variants. However, the vast quantum of data produced by NGS necessitates a robust and dependable mechanism for filtering irrelevant variants. Annotation-based variant filtering, a pivotal step in this process, demands a profound understanding of the case-specific conditions and the relevant annotation instruments. To tackle this complex task, we sought to design an accessible, efficient and more importantly easy to understand variant filtering tool. Results Our efforts culminated in the creation of 123VCF, a tool capable of processing both compressed and uncompressed Variant Calling Format (VCF) files. Built on a Java framework, the tool employs a disk-streaming real-time filtering algorithm, allowing it to manage sizable variant files on conventional desktop computers. 123VCF filters input variants in accordance with a predefined filter sequence applied to the input variants. Users are provided the flexibility to define various filtering parameters, such as quality, coverage depth, and variant frequency within the populations. Additionally, 123VCF accommodates user-defined filters tailored to specific case requirements, affording users enhanced control over the filtering process. We evaluated the performance of 123VCF by analyzing different types of variant files and comparing its runtimes to the most similar algorithms like BCFtools filter and GATK VariantFiltration. The results indicated that 123VCF performs relatively well. The tool's intuitive interface and potential for reproducibility make it a valuable asset for both researchers and clinicians. Conclusion The 123VCF filtering tool provides an effective, dependable approach for filtering variants in both research and clinical settings. As an open-source tool available at https://project123vcf.sourceforge.io , it is accessible to the global scientific and clinical community, paving the way for the discovery of disease-causing variants and facilitating the advancement of personalized medicine

Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients

Background: Anemia is a common complication of chronic renal failure due to reduce erythropoietin production by kidneys. Anemia treated with recombinant human erythropoietin (rHu-EPO). Pure red cell aplasia (PRCA) due to antibody productionagainst rHu-EPO is a rare but major complication of this drug. Objectives: The aim of this study was to determine the prevalence of PRCA due to antibodies in dialysis patients with resistant anemia who received erythropoietin. Patients and Methods: We studied 128 under maintenance hemodialysis patients more than 3 month in Kashan. In patients with anemia who received erythropoietin with dose requirements based on weight and anemia and without any another cause for anemia, evaluate for PRCA and anti-rHu-EPO antibody level were measured by ELISA. Results: In this research, 75 patients (58.6%) were male and 53 patients (41.4%) were female. The mean age of the patients was 59.05 ± 16.66 years. The result of analysis showed that 55 (43%) patients had anemia with hemoglobin level less than 10 mg/dL. Only 3 patients had PRCA and antibodies against erythropoietin in serum. There were no correlation between age, gender, cause of renal failure, hemodialysis duration, hemoglobin level, rHu-EPO dose and levels of anti-rHu-EPO antibody serum value. Conclusions: The result of this study indicated that administration of rHu-EPO in dialysis patients afflicted to kidney failure may cause PRCA especially through intravenous injection. However, this change is not statistically significant